-

Agilent Again Named One of Barron’s 100 Most Sustainable Companies

SANTA CLARA, Calif.--(BUSINESS WIRE)--For the sixth consecutive year, Agilent Technologies (NYSE: A) is ranked among the top 20 in Barron’s list of America’s 100 Most Sustainable Companies.

The ranking is based on the performance of the 1,000 largest publicly held companies on a variety of ESG (Environmental, Social and Governance) measures, including workplace diversity, greenhouse-gas emissions and waste. Barron’s conducted the evaluation with Calvert Research and Management, a leading responsible investment firm.

“We’re pleased to again be named in the Barron’s list of Most Sustainable Companies,” said Neil Rees, Agilent head of ESG Programs. “Agilent’s focus on sustainability is good for our company, our products, our customers and the environment. Sustainability has always been central to who we are and what we do as a company.”

A theme of this year’s ranking is the circular economy, which Barron’s defines as “keeping more products and materials recirculating to reduce waste and emissions.” This includes initiatives such as Agilent’s Certified Pre-Owned Instruments Program, which gives lab customers the option to trade in their used analytical instrument for cash or toward the purchase of a new instrument. Customers can also return select decommissioned instruments to Agilent for recycling. The program was recently recognized by Environment + Energy Leader for outstanding results in reducing waste.

Agilent has made progress in reducing waste across its global operations. In fiscal year 2021, Agilent achieved 94 percent solid waste diversion, just shy of a stated goal of 95 percent. And the company diverted 10,150 metric tons of total waste from disposal, including 7,708 metric tons of hazardous waste.

Other product sustainability initiatives at Agilent include designing analytical instruments to use less energy and produce less waste; product labeling that indicates the environmental footprint of select Agilent instruments; leadership in lab sustainability practices; and digital technology like CrossLab Connect that enable labs to operate more efficiently through automation, artificial intelligence, and virtual support.

Agilent also joined the How2Recycle program in 2022 to provide customers better information about the correct disposal of Agilent product packaging.

Read more about Agilent’s sustainability work in the company’s 2021 ESG report, including its commitment to reaching net-zero emissions by 2050.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...

Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. Second-quarter GAAP net income was $339 million, or $1.20 per share. This compares with $215 million, or $0.75 per share, in the second quarter of 2025. Non-GAAP net income(3) was $423 million, or $1.49 per share, during the quarter, compar...
Back to Newsroom